View Exam | PowerPak

1. Which of the following is an example of currently available agonist/antagonist abuse-deterrent formulations?

A. Niacin added to an opioid B. Capsaicin added to an opioid C. Naltrexone released when crushed D. Gel formation released when crushed

2. A chief obstacle in appropriate opioid prescribing is:

A. The stigma associated with prescribing opioids B. The cost of opioids C. The fear of contributing to abuse D. The knowledge of opioid pharmacology

3. Extended release, centrally acting analgesic medication having both µ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition, may NOT be particularly useful in the treatment of which of the following patients?

A. A patient with neuropathic pain B. A patient with acute pain C. A patient with comorbidities and taking multiple medications D. A patient with chronic lower back pain

4. Which of the following statements about equianalgesic conversion tables is FALSE?

A. By-mouth equivalents are often based on bioavailability of intramuscular versus by-mouth equivalents. B. Dosing for chronic and acute pain is often the same. C. Equianalgesic conversion tables do not work well with some drugs (eg, fentanyl, methadone, codeine) for various reasons. D. Not all agents are included in every table (eg, tramadol, tapentadol).

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an example of currently available agonist/antagonist abuse-deterrent formulations?

2. A chief obstacle in appropriate opioid prescribing is:

3. Extended release, centrally acting analgesic medication having both µ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition, may NOT be particularly useful in the treatment of which of the following patients?

4. Which of the following statements about equianalgesic conversion tables is FALSE?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an example of currently available agonist/antagonist abuse-deterrent formulations?

2. A chief obstacle in appropriate opioid prescribing is:

3. Extended release, centrally acting analgesic medication having both µ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition, may NOT be particularly useful in the treatment of which of the following patients?

4. Which of the following statements about equianalgesic conversion tables is FALSE?

« Return to Activity

Customers who Purchased
this Activity also Purchased